Kim Kamdar

Kim Kamdar joined Domain Associates in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Dr. Kamdar has been involved in cutting-edge therapeutic start-ups, using her expertise to identify companies with promising molecular and companion diagnostics that support personalized medicine.

Her present board memberships include Ariosa Diagnostics, Epic Sciences, Lithera, Obalon Therapeutics, ROX Medical, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. She was also involved with Corthera until its sale to Novartis in February 2010 and BiPar Sciences until its acquisition by Sanofi-Aventis in April 2009.

Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital and a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology.

Dr. Kamdar has authored ten papers and received seven patents. She completed her BA at Northwestern University and her PhD in biochemistry and genetics at Emory University. Dr. Kamdar serves as an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine and the Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. She is also a board member of San Diego’s CONNECT Foundation and the Hastings Center.